Janet Coller

Research Interests

Cancer Biology and Clinical Oncology Cardiac, Respiratory and Vascular Health Neuroscience, Behaviour and Brain Health Indigenous and Disadvantaged Health Translational Health Outcomes

Dr Janet Coller

Senior Lecturer

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Janet Coller is a Senior Lecturer in the Discipline of Pharmacology, the School of Medicine at the University of Adelaide. She has significant undergraduate teaching (into 6 courses) and administrative duties, including course coordination and Honours program coordination, accounting for 50% of her time. The remaining 50% is spent running her research program in clinical pharmaco- and immuno-genetics as head of the Clinical Pharmacogenomics Laboratory and member of the Cancer Treatment Toxicities Group

Cancer Treatment Toxicities Group

Our group members include undergraduate students, through to Honours and PhD, as well as postdoctoral researchers. We conduct research projects using cell culture models, transgenic rodents, and in patient cohorts (detailed below). Our mission is to improve cancer outcomes through personalising treatment and supportive care.

 
Available Research Projects

Research Project 1

Title: Gut microbiome composition as a predictive marker for cancer treatment outcomes

Project description: Patients with cancer are at high risk of microbiome dysbiosis (lack of bacterial diversity and/or overabundance of pathogenic species) due to frequent hospital visits, surgery, chemotherapy and radiation treatment, other medications (notably prophylactic antibiotics), changes in diet, and the presence of cancer itself. Having a diverse gut microbiota is considered protective against chemotherapy-induced infections, and pre-clinical work points to bacterial diversity as a key determinant of tumour response, gastrointestinal toxicity, and neuroinflammation. Thus the objective of this project is to explore links between microbiota, inflammatory responses, and chemotherapy treatment outcomes. Research techniques include mouse models of cancer treated with chemotherapy, bacterial gene sequencing, and a patient trial analysing longitudinal changes in microbiome composition following different cancer therapies.

Projects available for: Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

 

Research Project 2

Title: Toll-like receptor 4 and cancer treatment toxicities

Project description: Drugs and radiation used to treat cancer commonly cause damage to the normal gastrointestinal lining, leading to adverse symptoms such as intestinal inflammation and ulceration. There are currently no effective preventative strategies and a lack of understanding surrounding the mechanisms initiating damage. Recently, the innate immunity receptor, Toll-like Receptor 4 (TLR4), has been proposed to play a role in cancer therapy-induced gastrointestinal damage. As such, this project will investigate the effects of TLR4 gene deletion, or pharmacological inhibition, on the development of gastrointestinal inflammation in response to chemotherapy. This project will use rodent models treated with irinotecan. Research techniques include histological analysis, immunofluorescence, real time PCR and small animal handling. Results of this study will provide direct evidence of TLR4 signalling in mediating this important side effect of therapy.

Projects available for: Third Year / Honours / HDR

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

 

Research Project 3

Title: Role of microbial ablation on diarrhoea risk during treatment with EGFR inhibitors for breast cancer

Project description: Breast cancers that overexpress the human epidermal growth factor receptor (HER2) are treated by targeted small molecule inhibitors such as neratinib. HER2 and other members of the growth factor family are also expressed in the intestines, and treatment with neratinib is associated with chronic low-grade enterocolitis. We have developed a rat model in conjunction with our industry partners to explore the relationship between the composition of resident microbes in the intestine and the risk of severe treatment-related diarrhoea. The project will explore how different antibiotics impact the microbiome and how this affects onset and severity of neratinib diarrhoea. Techniques will include histopathology, immunohistochemistry and mucosal barrier permeability analysis.  

Projects available for: HDR (PhD and M.Phil)

Location: Helen Mayo Building

Research project start: Semester 1 and 2

Special requirements: Nil

Date Position Institution name
2015 - ongoing Senior Lecturer University of Adelaide
2013 - 2014 Lecturer University of Adelaide
2008 - 2012 FTT Fricker Research Fellow University of Adelaide
2004 - 2007 Postdoctoral Researcher University of Adelaide

Date Type Title Institution Name Country Amount
2007 Research Award Young Tall Poppy Science Award Australian Institute of Policy Science Australia -
2006 Research Award ASCEPT Mid-Career Best Paper Award ASCEPT Australia -
2004 Research Award APSA New Investigator Award Australasian Pharmaceutical Science Association Australia -
2002 Research Award ASCEPT Denis Wade Johnson & Johnson New Investigators Award ASCEPT Australia -

Date Institution name Country Title
2013 - 2013 University of Adelaide Australia Graduate Certificate in Education (Higher Education)
1996 - 2000 University of Adelaide Australia PhD (Medicine)
1995 - 1995 University of Adelaide Australia Bachelor of Science (Honours Pharmacology)
1992 - 1994 University of Adelaide Australia Bachelor of Science

Date Title Institution Country
2002 - 2004 NHMRC CJ Martin Research Fellow University of Adelaide Australia
2000 - 2002 NHMRC CJ Martin Research Fellow Dr Margarete Fischer Bosch Institute of Clinical Pharmacology Germany

Date Title Institution name Country
2015 Dangerous Goods Certification World Courier Aust Pty Ltd Australia
2014 AQIS Quarantine Approved Premises (Classes 2 to 8) Accreditation Australian Government Department of Agriculture Australia
2014 First Aid Certification St John Ambulance Australia Australia

Year Citation
2024 Alonge, M., Coller, J. K., Reuter, S. E., Jesudason, S., & Sallustio, B. C. (2024). Determining Plasma Tacrolimus Concentrations Using High-Performance LC-MS/MS in Renal Transplant Recipients.. Therapeutic drug monitoring, 46(1), 49-56.
DOI Scopus3 WoS2 Europe PMC2
2024 Sorby-Adams, A. J., Marian, O. C., Bilecki, I. M., Elms, L. E., Yassi, N., Hood, R. J., . . . Turner, R. J. (2024). NK1 tachykinin receptor antagonist treatment reduces cerebral edema and intracranial pressure in an ovine model of ischemic stroke. Journal of Cerebral Blood Flow and Metabolism, 44(10), 1759-1773.
DOI Scopus4 WoS1 Europe PMC1
2024 Dikeocha, I. J., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2024). Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical data. Clinical Nutrition Espen, 63, 462-475.
DOI Scopus1 WoS1 Europe PMC1
2024 White, C., Wardill, H., Paul, C., Price, T., Karapetis, C., Nalder, M., . . . Scott, R. J. (2024). DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. BMC cancer, 24(1), 1369.
DOI Scopus2 WoS2 Europe PMC2
2023 Crame, E. E., Nourmohammadi, S., Wardill, H. R., Coller, J. K., & Bowen, J. M. (2023). Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis. Journal of Cancer Research and Clinical Oncology, 149(7), 3009-3021.
DOI Scopus5 WoS4 Europe PMC3
2023 Tam, J. S. Y., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2023). Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation. Inflammation, 46(1), 103-114.
DOI Scopus12 WoS12 Europe PMC7
2023 Korver, S. K., Bowen, J. M., Gibson, R. J., Ball, I. A., Secombe, K. R., Wain, T. J., . . . Coller, J. K. (2023). Advanced statistics identifcation of participant and treatment predictors associated with severe adverse efects induced by fuoropyrimidine‑based chemotherapy. Cancer Chemother Pharmacol, 91(6), 507-521.
DOI Scopus3 WoS3 Europe PMC3
2023 Maddern, A. S., Coller, J. K., Bowen, J. M., & Gibson, R. J. (2023). The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse Effects. Cancers, 15(17), 4301-1-4301-22.
DOI Scopus10 WoS11 Europe PMC7
2022 Tam, J. S. Y., Crame, E. E., Elz, A. S., Coller, J. K., Wignall, A., Prestidge, C. A., & Bowen, J. M. (2022). Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity. Cancer Chemotherapy and Pharmacology, 90(3), 267-278.
DOI Scopus5 WoS4 Europe PMC5
2022 Tam, J. S. Y., Pei, J. V., Coller, J. K., Prestidge, C. A., & Bowen, J. M. (2022). Structural insight and analysis of TLR4 interactions with IAXO-102, TAK-242 and SN-38: an in silico approach.. In silico pharmacology, 11(1), 1-1-1-9.
DOI Europe PMC2
2022 Secombe, K. R., Crame, E. E., Tam, S. Y. J., Wardill, H. R., Gibson, R. J., Coller, J. K., & Bowen, J. M. (2022). Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.. Cancer Chemotherapy and Pharmacology, 89(2), 275-281.
DOI Scopus8 WoS8 Europe PMC7
2021 Bruning, E. E., Coller, J. K., Wardill, H. R., & Bowen, J. M. (2021). Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. Journal of Cellular Physiology, 236(2), 877-888.
DOI Scopus38 WoS32 Europe PMC30
2021 Tam, S. Y., Coller, J. K., Hughes, P. A., Prestidge, C. A., & Bowen, J. M. (2021). Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. Indian Journal of Gastroenterology, 40(1), 5-21.
DOI Scopus66 WoS59 Europe PMC56
2021 Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909.
DOI Scopus21 WoS21 Europe PMC14
2021 Steele, L., Klimas, N., Krengel, M., Quinn, E., Toomey, R., Little, D., . . . Sullivan, K. (2021). Brain–immune interactions as the basis of gulf war illness: Clinical assessment and deployment profile of 1990–1991 gulf war veterans in the gulf war illness consortium (gwic) multisite case-control study. Brain Sciences, 11(9), 17 pages.
DOI Scopus22 WoS20 Europe PMC22
2021 Crame, E. E., Bowen, J. M., Secombe, K. R., Coller, J. K., François, M., Leifert, W., & Wardill, H. R. (2021). Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. Inflammatory Intestinal Diseases, 6(4), 199-209.
DOI Scopus5 Europe PMC5
2021 Coller, J. K., Tuke, J., Wain, T. J., Quinn, E., Steele, L., Abreu, M., . . . Sullivan, K. (2021). Associations of immune genetic variability with gulf war illness in 1990–1991 gulf war veterans from the gulf war illness consortium (Gwic) multisite case-control study. Brain Sciences, 11(11), 1410-1-1410-7.
DOI Scopus6 WoS5 Europe PMC4
2020 Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., . . . Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431.
DOI Scopus536 WoS506 Europe PMC361
2020 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2020). No major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation. Frontiers in Pharmacology, 10, 1686-1-1686-8.
DOI Scopus4 WoS6 Europe PMC2
2020 Secombe, K. R., Van Sebille, Y. Z. A., Mayo, B. J., Coller, J. K., Gibson, R. J., & Bowen, J. M. (2020). Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome.. Integrative Cancer Therapies, 19, 1534735420928493-1-153473542092849-12.
DOI Scopus59 WoS54 Europe PMC50
2019 Tam, S. Y. J., Coller, J. K., Wignall, A., Gibson, R. J., Khatri, A., Barbé, C., & Bowen, J. M. (2019). Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis.. Annals of gastroenterology, 32(6), 584-592.
DOI Scopus7 WoS6 Europe PMC6
2019 Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019). The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer, 144(10), 2365-2376.
DOI Scopus72 WoS66 Europe PMC59
2019 Fakiha, K., Coller, J., Logan, R., Gibson, R., & Bowen, J. (2019). Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis. Supportive Care in Cancer, 27(6), 2313-2320.
DOI Scopus10 WoS9 Europe PMC9
2019 Korver, S. K., Gibson, R. J., Bowen, J. M., & Coller, J. K. (2019). Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.. Cancer Chemotherapy and Pharmacology, 83(2), 217-236.
DOI Scopus6 WoS4 Europe PMC4
2019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 29(1), 9-17.
DOI Scopus10 WoS10 Europe PMC9
2019 Sallustio, B. C., Noll, B. D., Coller, J. K., Tuke, J., Russ, G., & Somogyi, A. A. (2019). Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. British Journal of Clinical Pharmacology, 85(5), 1015-1020.
DOI Scopus5 WoS3 Europe PMC4
2019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?. Therapeutic Drug Monitoring, 41(4), 528-532.
DOI Scopus7 WoS7 Europe PMC7
2019 Coller, J. K., Ramachandran, J., John, L., Tuke, J., Wigg, A., & Doogue, M. (2019). The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome. British Journal of Clinical Pharmacology, 85(9), 2170-2175.
DOI Scopus15 WoS15 Europe PMC13
2019 Bowen, J. M., Gibson, R. J., Coller, J. K., Blijlevens, N., Bossi, P., Al-Dasooqi, N., . . . Elad, S. (2019). Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 27(10), 4011-4022.
DOI Scopus75 WoS60 Europe PMC46
2018 Md Dom, Z., Coller, J., Carroll, R., Tuke, J., McWhinney, B., Somogyi, A., & Sallustio, B. (2018). Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. British Journal of Clinical Pharmacology, 84(10), 2433-2442.
DOI Scopus19 WoS17 Europe PMC17
2018 Hu, R., Barratt, D., Coller, J., Sallustio, B., & Somogyi, A. (2018). CYP3A5*3 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic and Clinical Pharmacology and Toxicology, 123(3), 320-326.
DOI Scopus33 WoS30 Europe PMC28
2017 Coller, J. K., Bowen, J. M., Ball, I. A., Wardill, H. R., Van Sebille, Y. Z. A., Stansborough, R. L., . . . Gibson, R. J. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434.
DOI Scopus9 WoS8 Europe PMC8
2016 Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I., . . . Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15(11), 2767-2779.
DOI Scopus45 WoS41 Europe PMC31
2016 Somogyi, A., Sia, A., Tan, E., Coller, J., Hutchinson, M., & Barratt, D. (2016). Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 157(11), 2458-2466.
DOI Scopus25 WoS22 Europe PMC19
2016 Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258.
DOI Scopus22 WoS21 Europe PMC16
2016 Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I., . . . Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15(6), 1376-1386.
DOI Scopus124 WoS115 Europe PMC103
2015 Gibson, R. J., Bowen, J. M., & Coller, J. K. (2015). What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?. Future Oncology, 11(17), 2367-2370.
DOI Scopus10 WoS9 Europe PMC9
2015 Li, Y., Jackson, K., Slon, B., Hardy, J., Franco, M., William, L., . . . Somogyi, A. (2015). CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. British Journal of Clinical Pharmacology, 80(2), 276-284.
DOI Scopus58 WoS46 Europe PMC47
2015 Coller, J., White, I., Logan, R., Tuke, J., Richards, A., Mead, K., . . . Bowen, J. (2015). Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Supportive Care in Cancer, 23(5), 1233-1236.
DOI Scopus19 WoS18 Europe PMC12
2015 Corrigan, F., Wu, Y., Tuke, J., Coller, J., Rice, K., Diener, K., . . . Hutchinson, M. (2015). Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. Brain, Behavior, and Immunity, 45, 245-252.
DOI Scopus22 WoS22 Europe PMC21
2015 Somogyi, A., Coller, J., & Barratt, D. (2015). Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics, 97(2), 125-127.
DOI Scopus39 WoS25 Europe PMC26
2014 Westley, I., Coller, J., Ward, M., Evans, A., Morris, R., & Sallustio, B. (2014). A primer extension denaturing high-performance liquid chromatography method for the identification of three ABCC2 genetic polymorphisms. Journal of Liquid Chromatography and Related Technologies, 37(9), 1249-1256.
DOI
2014 Somogyi, A., Barratt, D., Ali, R., & Coller, J. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027.
DOI Scopus43 WoS41 Europe PMC38
2014 Mulholland, C., Somogyi, A., Barratt, D., Coller, J., Hutchinson, M., Jacobson, G., . . . Sleigh, J. (2014). Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience, 52(4), 497-506.
DOI Scopus17 WoS12 Europe PMC13
2014 Md Dom, Z., Noll, B., Coller, J., Somogyi, A., Russ, G., Hesselink, D., . . . Sallustio, B. (2014). Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. Journal of Chromatography B, 945-946, 171-177.
DOI Scopus22 WoS20 Europe PMC13
2013 Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2013). Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Therapeutic Drug Monitoring, 35(5), 617-623.
DOI Scopus34 WoS31 Europe PMC30
2013 Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Stanley, N., . . . Somogyi, A. (2013). The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metabolism and Disposition, 41(6), 1264-1272.
DOI Scopus43 WoS37 Europe PMC31
2012 Coller, J., Michalakas, J., James, H., Farquharson, A., Colvill, J., White, J., & Somogyi, A. (2012). Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. British Journal of Clinical Pharmacology, 74(5), 835-841.
DOI Scopus22 WoS18 Europe PMC15
2012 Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62.
DOI Scopus48 WoS43 Europe PMC38
2012 Gelston, E., Coller, J., Lopatko, O., James, H., Schmidt, H., White, J., & Somogyi, A. (2012). Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology, 73(5), 786-794.
DOI Scopus28 WoS25 Europe PMC21
2012 Coller, J., & Hutchinson, M. (2012). Implications of central immune signaling caused by drugs of abuse: Mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacology & Therapeutics, 134(2), 219-245.
DOI Scopus158 WoS144 Europe PMC141
2012 Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Coller, J., Rice, K., . . . Hutchinson, M. (2012). Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. British Journal of Pharmacology, 165(5), 1319-1329.
DOI Scopus69 WoS59 Europe PMC60
2011 Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2011). Measurement of Cyclosporine A in rat tissues and human kidney transplant biopsies - A method suitable for small (<1 mg) samples. Therapeutic Drug Monitoring, 33(6), 688-693.
DOI Scopus15 WoS15 Europe PMC14
2011 Coller, J., Cahill, S., Edmonds, C., Farquharson, A., Longo, M., Minniti, R., . . . White, J. (2011). OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 21(12), 902-905.
DOI Scopus40 WoS34 Europe PMC32
2011 Liu, L., Coller, J., Watkins, L., Somogyi, A., & Hutchinson, M. (2011). Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains. Brain Behavior and Immunity, 25(6), 1223-1232.
DOI Scopus56 WoS54 Europe PMC52
2011 Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Robertson, S., Coller, J., . . . Hutchinson, M. (2011). Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. Brain Behavior and Immunity, 25(Suppl 1), 155-164.
DOI Scopus71 WoS54 Europe PMC61
2010 Helsby, N., Hui, C., Goldthorpe, M., Coller, J., Soh, M., Gow, P., . . . Tingle, M. (2010). The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. British Journal of Clinical Pharmacology, 70(6), 844-853.
DOI Scopus48 WoS46 Europe PMC40
2009 Coller, J., Beardsley, J., Bignold, J., Li, Y., Merg, F., Sullivan, T., . . . Somogyi, A. (2009). Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRMI) and opioid defendence: A meta-analysis. Pharmacogenomics and Personalized Medicine, 2(1), 9-19.
Scopus28 WoS24
2009 Liu, L., Hutchinson, M., White, J., Somogyi, A., & Coller, J. (2009). Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 19(11), 869-876.
DOI Scopus42 WoS38 Europe PMC38
2009 Coller, J., Christrup, L., & Somogyi, A. (2009). Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology, 65(2), 121-139.
DOI Scopus102 WoS78 Europe PMC60
2008 Coller, J., Barratt, D., & Somogyi, A. (2008). Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clinical Pharmacology & Therapeutics, 83(5), 669-670.
DOI Scopus3 WoS2
2008 Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 65(3), 347-354.
DOI Scopus8 WoS8 Europe PMC6
2008 Buck, M., Coller, J., Murdter, T., Eichelbaum, M., & Knabbe, C. (2008). TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Research and Treatment, 107(1), 15-24.
DOI Scopus27 WoS24 Europe PMC19
2007 Inglis, S., Herbert, M., Davies, B., Coller, J., James, H., Horowitz, J., . . . Sallustio, B. (2007). Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics (Print Edition), 17(5), 305-312.
DOI Scopus8 WoS7 Europe PMC4
2007 Somogyi, A., Barratt, D., & Coller, J. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81(3), 429-444.
DOI Scopus302 WoS249 Europe PMC192
2007 Davies, B., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2007). CYP2B6 CYP2D6 and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metabolism and Disposition, 35(1), 128-138.
DOI Scopus24 WoS23 Europe PMC20
2007 Coller, J., Joergensen, C., Foster, D., James, H., Gillis, D., Christrup, L., & Somogyi, A. (2007). Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadon. International Journal of Clinical Pharmacology and Therapeutics, 45(7), 410-417.
DOI Scopus25 WoS22 Europe PMC19
2006 Coller, J., Barratt, D., Dahlen, K., Loennechen, M., & Somogyi, A. (2006). ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology & Therapeutics, 80(6), 682-690.
DOI Scopus137 WoS116 Europe PMC101
2006 Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2006). Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 843(2), 302-309.
DOI Scopus9 WoS10 Europe PMC4
2006 Barratt, D., Coller, J., & Somogyi, A. (2006). Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 141B(4), 323-331.
DOI Scopus49 WoS45 Europe PMC45
2006 Davies, B., Herbert, M., Culbert, J., Pyke, S., Coller, J., Somogyi, A., . . . Sallustio, B. (2006). Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 832(1), 114-120.
DOI Scopus17 WoS15 Europe PMC10
2006 Barratt, D., Coller, J., & Somogyi, A. (2006). ABCB1 haplotypes determine methadone dosage requirements. ACTA PHARMACOLOGICA SINICA, 27, 229.
2006 Coller, J. K., Plevin, D., Sallustio, B. C., Somogyi, A. A., & Morris, R. G. (2006). Relationship between the ABCB1 genetic polymorphism and clinical outcomes in renal transplant patients.. ACTA PHARMACOLOGICA SINICA, 27, 229.
2005 Davies, B., Coller, J., James, H., Somogyi, A., Horowitz, J., & Sallustio, B. (2005). The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. British Journal of Clinical Pharmacology, 61(3), 321-325.
DOI Scopus12 WoS12 Europe PMC6
2004 James, H., Coller, J., Gillis, D., Bahnisch, J., Sallustio, B., & Somogyi, A. (2004). A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. International Journal of Clinical Pharmacology and Therapeutics, 42(12), 719-723.
DOI Scopus19 WoS15 Europe PMC11
2004 Davies, B., Coller, J., James, H., Gillis, D., Somogyi, A., Horowitz, J., . . . Sallustio, B. (2004). Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology, 57(4), 456-463.
DOI Scopus6 WoS6 Europe PMC6
2004 Hutchinson, M., Menelaou, A., Foster, D., Coller, J., & Somogyi, A. (2004). CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57(3), 287-297.
DOI Scopus140 WoS107 Europe PMC86
2004 Coller, J., Krebsfaenger, N., Klein, K., Wolbold, R., Nussler, A., Neuhaus, P., . . . Murdter, T. (2004). Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. British Journal of Clinical Pharmacology, 57(1), 105-111.
DOI Scopus31 WoS26 Europe PMC19
2003 Coller, J. (2003). Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies. Clinical and Experimental Pharmacology and Physiology, 30(11), 845-848.
DOI Scopus20 WoS20 Europe PMC18
2003 Sallustio, B., Davies, B., Coller, J., James, H., Gillis, D., & Somogyi, A. (2003). Relationship between CYP2D6 genotype and plasma OH-perhexiline/perhexiline concentration ratio in angina patients.. Therapeutic Drug Monitoring, 25(4), 519.
2002 Coller, J., Krebsfaenger, N., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., . . . Murdter, T. (2002). The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. British Journal of Clinical Pharmacology, 54(2), 157-167.
DOI Scopus125 WoS108 Europe PMC96
2001 Murdter, T., Coller, J., Claviez, A., Schonberger, F., Hofmann, U., Dreger, P., & Schwab, M. (2001). Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clinical Chemistry, 47(8), 1437-1442.
DOI Scopus45 Europe PMC22
2001 Coller, J., Fritz, P., Zanger, U., Siegle, I., Eichelbaum, M., Kroemer, H., & Murdter, T. (2001). Distribution of microsomal epoxide hydrolase in humans: An immunohistochemical study in normal tissues, and benign and malignant tumours. Journal of Molecular Histology, 33(6), 329-336.
DOI Scopus44 WoS43 Europe PMC37
1999 Coller, J., Somogyi, A., & Bochner, F. (1999). Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica, 29(10), 973-986.
DOI Scopus33 WoS29 Europe PMC22
1999 Coller, J., Somogyi, A., & Bochner, F. (1999). Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.. British Journal of Clinical Pharmacology, 48(2), 158-167.
DOI Scopus42 WoS35 Europe PMC29
1998 Coller, J. K., Somogyi, A. A., & Bochner, F. (1998). Flunitrazepam oxidative metabolism in human liver microsomes. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R421.
1998 Coller, J., Somogyi, A., & Bochner, F. (1998). Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high performance liquid chromatography.. Journal of Chromatography B.., 719(1-2), 87-92.
DOI Scopus12 WoS11 Europe PMC7
1997 Coller, J., Somogyi, A., & Bochner, F. (1997). Association between CYP2C19 genotype and proguanil oxidative polymorphism.. British Journal of Clinical Pharmacology, 43(6), 659-660.
DOI Scopus24 WoS20 Europe PMC16

Year Citation
2016 Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger.
DOI
2012 Somogyi, A., & Coller, J. (2012). Drugs against acute and chronic pain. In P. Anzenbacher, & U. Zanger (Eds.), Metabolism of Drugs and Other Xenobiotics (1 ed., pp. 403-428). Germany: Wiley.
DOI Scopus4
2008 Somogyi, A., & Coller, J. (2008). Pharmacogenomics and Pharmacogenetics. In An Integrated Compendium of Twenty Encyclopedias (pp. 1-20). United Kingdom: Eolss Publishers.

Year Citation
2021 Crame, E., Wardill, H. R., Secombe, K., Coller, J., & Bowen, J. (2021). Intestinal epithelial TLR4 are crucial to chemotherapy toxicity development. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 110). WILEY.
2021 Tam, J., Coller, J., Hughes, P., Prestidge, C., & Bowen, J. (2021). Investigation of TLR4 antagonists for prevention of intestinal inflammation. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 113). WILEY.
2019 Bruning, E., Coller, J., Wardill, H., Secombe, K., & Bowen, J. (2019). Toll-like receptor 4 humanized C57BL/6 mouse intestinal permeability: A translational model for cancer treatment toxicity. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 34 (pp. 166). WILEY.
2018 Secombe, K., Bowen, J., Coller, J., Gibson, R., Stringer, A., Al-Dasooqi, N., . . . Wardill, H. R. (2018). Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 59). WILEY.
WoS2
2018 Korver, S. K., Bowen, J. M., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R., . . . Coller, J. K. (2018). Personalised supportive care for patients receiving 5-fluorouracil (5-FU): analysis of multivariate SNP risk prediction for GI toxicity. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 58-59). WILEY.
2016 Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia.
2011 Sallustio, B. C., Noll, B., Coller, J., Somogyi, A., van Gelder, T., Hesselink, D., & Morris, R. G. (2011). LC-MS/MS quantification of tacrolimus concentrations in small samples of kidney and liver tissue. In THERAPEUTIC DRUG MONITORING Vol. 33 (pp. 540). Stuttgart, GERMANY: LIPPINCOTT WILLIAMS & WILKINS.
2009 Somogyi, A. A., Gelston, E., Coller, J. K., White, J. M., & Schmidt, H. (2009). Methadone Inhibits CYP2D6 and UGT2B7 <i>In Vivo</i>: a Study using Codeine as the Substrate. In DRUG METABOLISM REVIEWS Vol. 41 (pp. 45-46). Lisbon, PORTUGAL: TAYLOR & FRANCIS INC.
WoS1
2009 Sallustio, B. C., Westley, I. S., Coller, J. K., Ward, M. B., Russ, G. R., & Morris, R. G. (2009). Frequency of Genetic Polymorphisms in the Promoter (C-24T), Exon 10 (G1249A) and Exon 28 (C3972T) Regions of <i>ABCC2</i> in Australian Renal Transplant Recipients and Donors. In THERAPEUTIC DRUG MONITORING Vol. 31 (pp. 656-657). Montreal, CANADA: LIPPINCOTT WILLIAMS & WILKINS.
2007 Sallustio, B. C., Davies, B. J., Herbert, M. K., Coller, J. K., Somogyi, A. A., & Milne, R. W. (2007). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 extensive and poor metabolisers. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 478). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS.
2003 Krebsfaenger, N., Coller, J., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., . . . Doehmer, J. (2003). The influence of CYP2B6, CYP2C9, and CYP2D6 genotypes on the formation of the potent antiestrogen Z-4-hydroxy-tamoxifen in human liver. In DRUG METABOLISM REVIEWS Vol. 35 (pp. 131). DIJON, FRANCE: TAYLOR & FRANCIS LTD.
2003 Krebsfaenger, N., Muerdter, T. E., Coller, J., Zanger, U. M., Eichelbaum, M., Coecke, S., & Doehmer, J. (2003). Expression of polymorphic CYP2D6 variants in V79 cells and their predictive value for clinical studies. In DRUG METABOLISM REVIEWS Vol. 35 (pp. 131). DIJON, FRANCE: TAYLOR & FRANCIS LTD.
2001 Mürdter, T. E., Claviez, A., Coller, J., Hofmann, U., Dreger, P., Eichelbaum, M., & Schwab, M. (2001). A new highly sensitive liquid chromatography-mass spectrometry assay for detection of busulfan:: Evaluation of pharmacokinetics after intraveneous administration. In NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Vol. 363 (pp. R122). SPRINGER-VERLAG.

Year Citation
2019 Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017 Bowen, J., Ball, I., Thompson, S., Irvine, T., Chiam, K., Hussey, D., . . . Keefe, D. (2017). Identification of Inflammatory Markers of Chemoradiotherapy-Induced Gastrointestinal Toxicity in Oesophageal Cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017 Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2017 Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (<i>IL1B</i>) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2015 Dom, Z. M., Coller, J., Carroll, R., Somogyi, A., & Sallustio, B. (2015). Intra-Lymphocyte Concentrations of Mycophenolic Acid Correlate With the Incidence of Early Graft Rejection in Renal Transplant Recipients. Poster session presented at the meeting of AMERICAN JOURNAL OF TRANSPLANTATION. Philadelphia, PA: WILEY-BLACKWELL.
2015 Dom, Z. I. M., Westley, I. S., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2015). Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of mycophenolic acid in renal transplant recipients. Poster session presented at the meeting of Abstracts of the 2015 Golden Helix Symposium - Next Generation Pharmacogenomics, as published in Public Health Genomics. Karger.
DOI WoS1
2014 Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Currow, D., . . . Somogyi, A. (2014). Cyp2B6*6 Allele Alters Ketamine'S Pharmacokinetics In Chronic Pain Patients And Metabolism In Vitro. Poster session presented at the meeting of Drug Metabolism Reviews. Toronto, CANADA: Informa Healthcare.
DOI Europe PMC3
2013 Bowen, J., White, I., Tuke, J., Logan, R., Richards, A., Mead, K., . . . Coller, J. (2013). IMMUNE GENETIC VARIABILITY IS ASSOCIATED WITH RISK OF SEVERE GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH FLUOROURACIL. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2013 Coller, J., Tuke, J., Ramachandran, J., Wigg, A. J., & Doogue, M. (2013). Relationship between CYP3A5, ABCB1 and immune genetics and tacrolimus concentrations, and the occurrence of nephrotoxicity and rejection following liver transplantation. Poster session presented at the meeting of HEPATOLOGY. Washington, DC: WILEY-BLACKWELL.
2013 Dom, M. Z., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2013). Impact of Recipient and Donor Multidrug Resistance Protein 2 Genetic Variability on Mycophenolic Acid Pharmacokinetics Following Kidney Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS.
2013 Sallustio, B., Noll, B., Coller, J., & Somogyi, A. (2013). Association Between Intra-Renal P-gp Expression and Cyclosporine Concentrations in Renal Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS.
2011 Somogyi, A. A., Coller, J. K., Foster, D. B. F., & Li, Y. (2011). ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS. Poster session presented at the meeting of BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. WILEY-BLACKWELL.
WoS1

Date Role Research Topic Program Degree Type Student Load Student Name
2023 Co-Supervisor Chronic abdominal pain in Australian adolescents and nature-based intervention Master of Philosophy (Medical Science) Master Part Time Mrs Trish Serocki
2023 Co-Supervisor Chronic abdominal pain in Australian adolescents and nature-based intervention - Master Full Time Mrs Trish Serocki

Date Role Research Topic Program Degree Type Student Load Student Name
2019 - 2025 Co-Supervisor Using Pharmacokinetic Principles to Improve the Safety of Tacrolimus in Kidney Transplant Recipients Doctor of Philosophy Doctorate Part Time Miss Mirabel Alonge
2019 - 2023 Co-Supervisor The Role of TLR4 in Chemotherapy-Induced Toxicity, Immunity and Tumour Growth Doctor of Philosophy Doctorate Full Time Mrs Elise Ellen Crame
2018 - 2022 Co-Supervisor Exploring the Effects of Toll-Like Receptor 4 Antagonism on Gastrointestinal Mucositis and Tumour Activity Doctor of Philosophy Doctorate Full Time Miss Shu Yie Janine Tam
2017 - 2021 Co-Supervisor Exploration of the gut microbiome as a predictive factor for cancer treatment-induced gastrointestinal toxicity Doctor of Philosophy Doctorate Full Time Miss Kate Rebecca Secombe
2016 - 2020 Principal Supervisor Identifying potential genetic, phenotypic and epigenetic predictive markers in the Toll-like receptor/Interleukin-1 domain innate immune signalling pathway for severe gastrointestinal toxicity risk following 5-Fluorouracil-based therapy Doctor of Philosophy Doctorate Full Time Miss Samantha Kaitlyn Korver
2015 - 2019 Co-Supervisor Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes Doctor of Philosophy Doctorate Full Time Ms Rong Hu
2011 - 2017 Co-Supervisor Mycophenolic Acid Pharmacokinetics and Clinical Outcomes in Renal Transplantation: Effect of ABCC2 Haplotype Analysis and Distribution into Lymphocytes and Kidney Doctor of Philosophy Doctorate Full Time Mr Zaipul Izwan Md Dom
2010 - 2014 Co-Supervisor Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Doctor of Philosophy Doctorate Full Time Mr Yibai Li
2010 - 2015 Co-Supervisor A Study Linking Toll-like Receptors and Irinotecan-induced Gastrointestinal Mucositis Doctor of Philosophy Doctorate Full Time Mrs Khloud Ghazi Fakiha
2009 - 2011 Co-Supervisor CNS Immune Signalling and Drug Addiction: Role of Interleukin-1 Beta Doctor of Philosophy Doctorate Full Time Mr Liang Liu
2008 - 2011 Co-Supervisor The Neuroimmunopharmacology of Alcohol Doctor of Philosophy Doctorate Full Time Miss Yue Wu
2005 - 2010 Co-Supervisor Pharmacogenomics of ABCB1 in Maintenance Pharmacotherapies for Opioid Dependence Doctor of Philosophy Doctorate Full Time Dr Daniel Barratt
2003 - 2008 Co-Supervisor The Stereoselective Pharmacokinetics of the Enantiomers of Perhexiline in Poor and Extensive Metabolisers of the Cytochrome P450 2D6 Doctor of Philosophy Doctorate Full Time Mr Benjamin Davies

Date Role Membership Country
2016 - ongoing Member MASCC United States
2012 - ongoing Member PNIRS United States
2004 - ongoing Member APSA Australia
1998 - 2015 Member ISSX United States
1995 - ongoing Member ASCEPT Australia

Date Role Editorial Board Name Institution Country
2012 - ongoing Board Member Frontiers in Pharmacogenetics - -
2007 - 2012 Board Member The Open Drug Metabolism Journal - -

Connect With Me

External Profiles

Other Links